REG - Byotrol PLC - Trading Update and Notice of Results

ByotrolAnnouncement

11/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220711:nRSK9202Ra&default-theme=true

RNS Number : 9202R  Byotrol PLC  11 July 2022

 

 

 

Byotrol plc ("Byotrol" or the "Company")

 

Post Close Trading Update

Notice of Results

 

 

Byotrol plc (AIM: BYOT), the infection prevention technology company, today
provides an update on trading for the year ended 31 March 2022.  Subject to
audit, it is expected that the results will be in line with the trading
updates made ahead of the year-end including:

 

·      Sales of £6.3m, comprising £5.2m from product sales and £1.1m
from IP sales and royalties;

·      Positive Adjusted EBITDA, before exceptional items;

·      Cash at year end of £1.1m.

 

The Board is pleased to report that for the first time we include in IP
revenue a contribution from Solvay for Byotrol's on-going participation in
Solvay's sales of Actizone 24 hour surface sanitiser. As previously announced,
this is a small quantum, but a very encouraging first financial step.

 

Post-period end

 

Since the year end, the Company has closed two significant new IP
agreements.

 

1.    a multi-year, three-way, exclusive agreement between the Company, our
US licensee Integrated Resources International (IRI), and a significant US
distribution company ("USCo"), to sub-register with the US EPA and then sell
the Byotrol24 surface sanitiser under USCo branding into US Professional
markets. Should formal registration be achieved - expected within 12 months -
sales by IRI to USCo will accrue additional royalties to Byotrol. The Company
expects to have further clarity on this when it reports its audited results
for the year.

2.    a seven year license in alcohol-free hand sanitisers with Rentokil
Initial Plc .  This is a non-exclusive license of rights to our proprietary
hand sanitising formulation for distribution by Rentokil under its own brand
into serviced washrooms, predominantly in the UK and Europe

 

Byotrol expects to release audited final results for the full year to 31 March
2022 before the end of next month.

 

David Traynor, CEO of Byotrol plc, commented:

 

"We are pleased to confirm that our results for the past year will meet
expectations as described in our trading update of early March.

 

We are also pleased to announce further progress in licensing and IP, with two
new agreements with best-in-class names in their respective markets, and
confirmation that Solvay's Actizone24 product is now gaining commercial
traction.

 

Underlying market trends remain very favourable for our long-term growth.  We
look forward to providing a further update on product and IP sales with the
release of our final audited results, which is expected in August."

 

The information communicated in this announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU) No.
596/2014.

 

 

For further information, visit www.byotrolplc.com (http://www.byotrolplc.com)
, follow on twitter @byotrol, or contact

 

Byotrol plc

David Traynor - Chief Executive Officer

Chris Sedwell - Chief Financial
Officer
             01925 742 000

 

finnCap

Geoff Nash/ James Thompson -  Corporate
Finance

Richard Chambers - ECM -
 
020 7220 0500

 

Flagstaff Strategic and Investor
Communications
020 7129 1474

Tim Thomson/Andrea Seymour/Fergus Melon
 
byotrol@flagstaffcomms.com

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading infection prevention and
control company, operating globally in the animal health, human health,
facilities management, and consumer sectors.

 

Byotrol develops unique antimicrobial technologies for use on surfaces, skin
and instruments, which it then commercialises through market-leading
distribution partners in each sector.

 

Byotrol's antimicrobial technologies can be licensed for use in leading
brands, to significantly improve their product claims, while reassuring
consumers and end-users of their efficacy and quality.

 

Founded in 2005, the Company develops technologies and products with the aim
of providing easier, safer and cleaner lives for everyone.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTMZGGNNRZGZZM